Sign in

Journal of Medical Economics

@jme-journal.bsky.social
93 followers 231 following 50 posts

Open access, medical economics journal. Publishing leading studies that determine the cost-effectiveness of treatment and high-quality economic assessments. Impact Factor: 3.0 and CiteScore: 4.4 (2024) Access the journals homepage -> bit.ly/3I4GZvn

PostsRepliesMedia
Journal of Medical Economics @jme-journal.bsky.social · 23/09/2026
New paper tackles a key challenge in #healtheconomics: evaluating diagnostics & medical devices with limited comparative data. The authors use #bladdercancer diagnostics as a case study to demonstrate novel methodological approaches. Read the article in full here 👉 bit.ly/3TJy9ck #HEOR #modelling
bit.ly
Addressing the challenges of health economic modelling in the context of suboptimal evidence base – case study based on a comparison between photodynamic diagnosis and narrow band imaging in non-muscle invasive bladder cancer
Standard economic models, which have been developed to reflect typical data availability for pharmaceutical products, often struggle with non-pharmaceutical interventions like diagnostics and medic...
000
Journal of Medical Economics @jme-journal.bsky.social · 17/09/2026
New research reveals the hidden workplace cost of #handeczema: $30K per claim in manufacturing + significant work disruption. Our 14-year study shows employers need to prioritize early diagnosis & prevention of occupational hand eczema. The impact is bigger than you think. 📊 bit.ly/4hgD4cz #HEOR
bit.ly
Hand eczema in US employees: a retrospective observational study of workers’ compensation and medical claims
This research quantified the impact of hand eczema (HE) on US employees.Retrospective observational analysis of real-world data from >500 large, self-insured employers from 2010 through 2024. The d...
000
Journal of Medical Economics @jme-journal.bsky.social · 09/09/2026
𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐞𝐝 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 New #costeffectiveness analysis of xanomeline and trospium chloride as first-line #schizophrenia treatment from a US payer perspective: ⭐ vs. generics: more costly but more effective; cost-effective ICERs ⭐ vs. branded: less costly AND more effective Read more 👉 bit.ly/4ikCFrQ
bit.ly
Cost-effectiveness analysis of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the US
The objective of this analysis was to evaluate the cost-effectiveness of xanomeline and trospium chloride (KarXT) as first line (1 L) treatment for adults with schizophrenia from a third-party US p...
000
Journal of Medical Economics @jme-journal.bsky.social · 02/09/2026
Just in case you missed it! Our latest editorial features insights from Editors-in-Chief and readers on the #healtheconomics topics that will be important through 2026-27. Access the full editorial here 👉 bit.ly/4qH4o8a #HEOR #medicaleconomics #pharmacoeconomics
bit.ly
What to expect in 2026–2027: important health economics and outcomes research topics
Published in Journal of Medical Economics (Vol. 29, No. 1, 2026)
000
Journal of Medical Economics @jme-journal.bsky.social · 27/08/2026
𝐖𝐚𝐧𝐭 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐰𝐡𝐢𝐜𝐡 #𝐇𝐄𝐎𝐑 𝐭𝐨𝐩𝐢𝐜𝐬 𝐰𝐢𝐥𝐥 𝐛𝐞 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭 𝐢𝐧 𝟐𝟎𝟐𝟔-𝟐𝟕? Read our latest editorial featuring expert opinions from the Editors-in-Chief and readers of Taylor & Francis's premier health economics journals. Read the full editorial here 👉 bit.ly/4qH4o8a #healtheconomics #pharmacoeconomics #RWE
bit.ly
What to expect in 2026–2027: important health economics and outcomes research topics
Published in Journal of Medical Economics (Vol. 29, No. 1, 2026)
000
Journal of Medical Economics @jme-journal.bsky.social · 25/08/2026
Thrilled to share an article I co-authored with the Editors-in-Chief of Taylor & Francis's #healtheconomics journals! We surveyed 200+ #HEOR experts to identify key topics for 2026-27. Read the article to discover the results and the EiC's insights on the top 5 topics 👉 bit.ly/4ca6tTZ
000
Journal of Medical Economics @jme-journal.bsky.social · 11/08/2026
💡𝐀𝐫𝐭𝐢𝐜𝐥𝐞 𝐞𝐧𝐡𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬: 𝐢𝐧𝐟𝐨𝐠𝐫𝐚𝐩𝐡𝐢𝐜𝐬💡 Check out this excellent example from a societal cost impact analysis on #Parkinson's treatments. Click the link to view the article and infographic 👉 bit.ly/4xFat7r Why add infographics: ✅ Free to add ✅ Boosts engagement and impact #HEOR #Healtheconomics
bit.ly
Subcutaneous foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson’s disease (aPD): societal cost impact analysis for the UK, France, Germany, Spain, and Canada
The costs associated with advanced Parkinson’s disease (aPD) extend beyond direct medical expenditure. As symptoms become more severe, professional and informal personal care costs are likely to ex...
000
Journal of Medical Economics @jme-journal.bsky.social · 05/08/2026
Great example of how #graphicalabstracts amplify research impact! This study examines the #healtheconomic impact of continuous vital sign monitoring across 5 EU countries. The visual summary makes findings accessible to #clinicians, #patients & #policymakers alike. Check it out 👉 bit.ly/4yYb45v
bit.ly
Health-economic impact of implementing continuous vital sign monitoring in post-surgical patients in five European countries
Hospitals, in particular intensive care units (ICUs), account for a large proportion of healthcare costs and environmental burden. Preventing unexpected patient transfer to ICU via continuous vital...
000
Journal of Medical Economics @jme-journal.bsky.social · 23/07/2026
Happy Thursday! ☀️ Delighted to share the "Spotlight on Health Economics" newsletter! It consolidates 14 Taylor & Francis #healtheconomics journals into one monthly digest featuring: ⭐ Article highlights ⭐ Publishing news & ethics updates ⭐ KOL interviews Sign up 👉 bit.ly/44K1khm #HEOR
bit.ly
Unlock Insights with Spotlight on Health Economics
Stay informed with Spotlight on Health Economics, a regular newsletter designed to keep you updated with an expert review of the latest research.
000
Journal of Medical Economics @jme-journal.bsky.social · 21/07/2026
📣 New study challenges #colorectalcancer screening assumptions Stool DNA testing (every 3 yrs) may be more effective than colonoscopy (every 10 yrs) in real-world settings. Why? Better adherence + more frequent screening = improved detection Click for the full article 👉 bit.ly/4whfdjl #HEOR
000
Journal of Medical Economics @jme-journal.bsky.social · 16/06/2026
Want to stay at the forefront of #healtheconomics? Our new monthly newsletter, 𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 𝐄𝐜𝐨𝐧𝐨𝐦𝐢𝐜𝐬, delivers: ✅ Latest breakthrough studies ✅ Emerging research trends ✅ Expert insights shaping #pharmacoeconomics #medicaleconomics
invt.io
Sign up to our newsletter: Spotlight on Health Economics
Sign up here
000
Journal of Medical Economics @jme-journal.bsky.social · 05/06/2026
📊 Stay informed on HEOR trends! Taylor & Francis is launching the "𝐒𝐩𝐨𝐭𝐥𝐢𝐠𝐡𝐭 𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 𝐄𝐜𝐨𝐧𝐨𝐦𝐢𝐜𝐬" newsletter. Your source for the latest HEOR research and insights. Sign up using the link 👉 bit.ly/4g2o176 #healtheconomics #HEOR #pharmacoeconomics #medicaleconomics #healthpolicy #healthcare
010
Journal of Medical Economics @jme-journal.bsky.social · 27/04/2026
𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐜𝐨𝐧𝐬𝐢𝐝𝐞𝐫𝐞𝐝 #𝐩𝐥𝐚𝐢𝐧𝐥𝐚𝐧𝐠𝐮𝐚𝐠𝐞𝐬𝐮𝐦𝐦𝐚𝐫𝐢𝐞𝐬 𝐟𝐨𝐫 𝐲𝐨𝐮𝐫 𝐚𝐫𝐭𝐢𝐜𝐥𝐞? These valuable article enhancements improve access to research, help readers identify and save key information, and expand readership to #patientgroups, #policymakers, and #practitioners. See how it's done! 👉 bit.ly/4czHw55 #HEOR
bit.ly
Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe
Despite clinical efficacy and cost-effectiveness, time to reimbursement for chimeric antigen receptor (CAR) T-cell therapies varies greatly across Europe. We examined these differences, and quantif...
000
Journal of Medical Economics @jme-journal.bsky.social · 20/04/2026
📈 Recommended Reading Our latest research article evaluates the cost-effectiveness of the #GAAD algorithm for #hepatocellularcarcinoma surveillance for patients with compensated cirrhosis. To read the full article, click the link 👉 bit.ly/4mFS4TD #healtheconomics #HEOR #Pharmacoeconomics
bit.ly
Cost-effectiveness of the GAAD algorithm for hepatocellular carcinoma surveillance of patients with compensated cirrhosis: a model-based analysis using Italian real-world data
Early detection of hepatocellular carcinoma (HCC) in patients with compensated cirrhosis (CC) is critical for improving prognosis. The GAAD algorithm (gender [biological sex], age, alpha-fetoprotei...
000
Journal of Medical Economics @jme-journal.bsky.social · 02/04/2026
📢 𝐑𝐞𝐜𝐞𝐧𝐭𝐥𝐲 𝐩𝐮𝐛𝐥𝐢𝐬𝐡𝐞𝐝 I'm pleased to share our latest policy paper, which brings together insights from clinicians, health economists, outcomes researchers, and policy experts to address critical gaps in early-stage #cancercare. Access the article in full here 👉 bit.ly/485EbYI #healthpolicy #HEOR
bit.ly
Rationale and recommendations for improving early-stage oncology diagnosis, treatment, and access
Detecting and treating cancer at an early stage is critical for improving patient survival, quality of life, and health system efficiency. Early diagnosis offers substantial clinical benefits, redu...
000
Journal of Medical Economics @jme-journal.bsky.social · 25/03/2026
Excited to share our latest research article that compares the cost-effectiveness of #𝐫𝐢𝐛𝐨𝐜𝐢𝐜𝐥𝐢𝐛 versus #𝐩𝐚𝐥𝐛𝐨𝐜𝐢𝐜𝐥𝐢𝐛 as first-line treatment for HR+/HER2–advanced breast cancer in postmenopausal women from a Medicare perspective. Read the full article here 👉 bit.ly/4szheFD #HealthEconomics #HEOR
000
Journal of Medical Economics @jme-journal.bsky.social · 10/02/2026
📣Recommended reading📣 Our latest paper assesses the relationship between #Alkalinephosphatase levels, #healthcareresourceutilisation, and costs in #𝘱𝘳𝘪𝘮𝘢𝘳𝘺𝘣𝘪𝘭𝘪𝘢𝘳𝘺𝘤𝘩𝘰𝘭𝘢𝘯𝘨𝘪𝘵𝘪𝘴 patients in the US. View the full article here 👉 bit.ly/4aLMEB5 #healtheconomics #HEOR #economicimpact
bit.ly
Association between elevations in alkaline phosphatase and healthcare utilization and costs among individuals with primary biliary cholangitis in the United States
Alkaline phosphatase (ALP) is a key biomarker in the management of primary biliary cholangitis (PBC). However, evidence of economic benefits of normal ALP is limited. We evaluated the relationship ...
000
Journal of Medical Economics @jme-journal.bsky.social · 08/12/2025
Read our latest real-world analysis that reveals the burden and financial impact of #cardiacarrhythmias in #COPD patients on #healthcaresystems. It also explores how early detection through ambulatory electrocardiogram monitoring could mitigate this burden. Click for the article👉 bit.ly/4rPcFXU
000
Journal of Medical Economics @jme-journal.bsky.social · 25/11/2025
📣 Explore our latest review examining the impact of avoiding or delaying progression to 𝐦𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐜𝐚𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧-𝐫𝐞𝐬𝐢𝐬𝐭𝐚𝐧𝐭 𝐩𝐫𝐨𝐬𝐭𝐚𝐭𝐞 𝐜𝐚𝐧𝐜𝐞𝐫 on health-related quality of life, mortality, and economic outcomes. Click the link to read the article in full 👉 bit.ly/49FgyIe #prostatecancer #healtheconomics
bit.ly
Prostate cancer progression: a scoping review, pharmacoeconomic assessment, and evaluation of quality of life
Prostate cancer is the most common malignancy in men and a leading cause of cancer-related death. Progression from non-metastatic castration-resistant prostate cancer (nmCRPC) to metastatic CRPC (m...
010
Journal of Medical Economics @jme-journal.bsky.social · 27/10/2025
𝐍𝐞𝐰 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 Our latest article forecasts the #burden and #healthcarecosts of obesity in the US from 2023 to 2060. It also identifies strategic intervention windows for obesity treatments to maximise cost savings. Click the link to read the full article 👉 bit.ly/48TDwuR #HEOR #Healtheconomics
000
Journal of Medical Economics @jme-journal.bsky.social · 20/10/2025
Our latest article examines 𝐈𝐜𝐨𝐝𝐞𝐜's cost-effectiveness compared to other long-acting insulins, including glargine, detemir, and degludec. Discover the authors' findings by clicking the link 👉 bit.ly/4higT5r #diabetes #bloodsugar #costeffectiveness #healtheconomics #HEOR
000
Reposted by Journal of Medical Economics
NewAmsterdam Pharma Corporation @newamsterdampharma.bsky.social · 25/09/2025
A new analysis in @jme-journal.bsky.social identifies a costly gap in heart health. A majority of Americans with hypercholesterolemia are on statins, but most don't hit their LDL-C targets. Getting to goal was associated with a 50% reduction in cardiovascular events. bit.ly/48xvWWf
New research in the Journal of Medical Economics: Assessment of unmet clinical needs and healthcare resource use among statin-treated patients with or at risk of developing atherosclerotic cardiovascular disease
021
Journal of Medical Economics @jme-journal.bsky.social · 17/09/2025
🚨 Available now🚨 Our latest review provides an essential insight into how #patientreportedoutcomemeasures can be included in #costeffectiveness models that inform #healthtechnologyassessments of non-oncology treatments. Read it here 👉 www.tandfonline.com/doi/full/10....
tandfonline.com
Use of patient-reported outcome measures in cost-effectiveness models informing health technology assessments of non-oncology treatments: a review
Including patient-reported outcome measures (PROMs) in cost-effectiveness models (CEMs) represents an important opportunity to reflect patients’ perspectives in health technology assessments (HTAs)...
000
Journal of Medical Economics @jme-journal.bsky.social · 15/09/2025
🚨 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐞𝐝 𝐚𝐫𝐭𝐢𝐜𝐥𝐞 🚨 Discover how Audrey Petitjean et al. assessed the use of external evidence for overall survival estimation in #oncology single-technology appraisals by the National Institute for Health and Care Excellence. Click the link for the full article 👉 bit.ly/4glH9ey #NICE #HEOR
bit.ly
Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs
To assess use of external evidence for overall survival (OS) estimation in oncology single-technology appraisals (STAs) by the National Institute for Health and Care Excellence (NICE).STAs for onco...
000
Journal of Medical Economics @jme-journal.bsky.social · 10/09/2025
📢 𝑹𝒆𝒄𝒐𝒎𝒎𝒆𝒏𝒅𝒆𝒅 𝒓𝒆𝒂𝒅 Discover the impact of treatment failure for #migraine on lost earnings among #triptan non-responders in the general population of #Denmark. Click the link for the full article 👉 bit.ly/4piFVoy
bit.ly
Lost earnings among triptan non-responders in the general population of Denmark: a measure of disproportionate migraine-attributed burden and of unrecognised and unmet treatment need
Migraine leads to substantial healthcare utilization and associated costs. However, much higher costs are attributed to lost productivity. The impact of effective migraine treatment on these costs,...
000
Journal of Medical Economics @jme-journal.bsky.social · 03/09/2025
🚨 𝐍𝐨𝐰 𝐨𝐧𝐥𝐢𝐧𝐞 🚨 Our latest article evaluates the budgetary impact of pathways using cT1 versus SoC (liver biopsy or VCTE) to assign suspected #MASH patients to #resmetirom. See the graphical abstract below for an overview of the study. Click the link for the full article 👉 bit.ly/4g3dLJQ
100
Journal of Medical Economics @jme-journal.bsky.social · 02/09/2025
📢 𝑱𝒖𝒔𝒕 𝒑𝒖𝒃𝒍𝒊𝒔𝒉𝒆𝒅: Our latest article assesses the economic impact of #influenzavaccination across the #UAE and #Iraq. Click the link to access it in full 👇 bit.ly/3K2tz3u Congratulations to the authors—it was lovely to collaborate with you. #publichealth #costeffectiveness #HEOR
bit.ly
Cost-effectiveness analysis of seasonal influenza vaccination compared to no vaccination in the United Arab Emirates and Iraq
Influenza is often considered a trivial illness due to its generally mild symptoms. This perception overlooks the extensive scale of people affected annually, many of whom experience severe complic...
000
Journal of Medical Economics @jme-journal.bsky.social · 27/08/2025
📢 𝐑𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐞𝐝 𝐫𝐞𝐚𝐝𝐢𝐧𝐠 " #Costeffectiveness of wastewater and environmental monitoring of #respiratorysyncytialvirus to guide universal infant immunoprophylaxis in #Canada" Click the link to access the article in full or read the plain language summary below 👉 bit.ly/45BQlb3 #HEOR #Healtheconomics
000
Journal of Medical Economics @jme-journal.bsky.social · 22/08/2025
We're excited to announce that our website now features a dedicated multimedia section showcasing our #videoabstracts. Access this content here👉 bit.ly/4oJik05 We have also expanded the extenders we offer to include #audioabstracts, #podcasts, and #videoarticles. Get in touch to find out more.
bit.ly
Video & audio content published in Journal of Medical Economics
Explore video and audio content published within Journal of Medical Economics articles.
000
Journal of Medical Economics @jme-journal.bsky.social · 07/08/2025
📣Available now View our webinar which provides an essential insight into the #submission and #peerreview processes, such as best practices for what should be included in your manuscript. 👉 bit.ly/40XWFaa #publishing #AI
bit.ly
The Complete Publication Journey: Insights into strategic planning, submission guidelines and research reach - Author Services
Preparing a publication plan for your manuscript is extremely beneficial, helping with maximizing the impact of your research further down the publication pipeline.
001
Journal of Medical Economics @jme-journal.bsky.social · 22/07/2025
We are currently commissioning articles for an article collection titled "Health Economics in #Cancer Treatment and Care" If you're interested in submitting, get in touch 👉 mike.gregg@tandf.co.uk So far, four articles have been published in the collection — you can access them here.👉 bit.ly/4167G9h
bit.ly
Health economics in cancer treatment and care
Explore the article collection: Health economics in cancer treatment and care. Published in Journal of Medical Economics.
000
Journal of Medical Economics @jme-journal.bsky.social · 25/06/2025
🚨 𝐑𝐞𝐜𝐨𝐦𝐦𝐞𝐧𝐝𝐞𝐝 𝐫𝐞𝐚𝐝🚨 Discover the preference of patients and physicians for treatments of Hepatitis C infections in Japan in this article. Click the link for the full article 👉 bit.ly/46e4njD #patientpreference #physicianpreference #hepatitisC #HEOR
bit.ly
Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment
This study was performed to evaluate patients’ and physicians’ preferences regarding hepatitis C virus (HCV) treatment in Japan, particularly focusing on direct-acting antivirals. Understanding the...
000
Journal of Medical Economics @jme-journal.bsky.social · 19/06/2025
🚨𝐖𝐞 𝐧𝐞𝐞𝐝 𝐲𝐨𝐮𝐫 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬🚨 What will shape #pharmacoeconomics in 2026? Your expert opinion matters! Take our quick survey, share your perspective, and be in for a chance to win a $40 Amazon gift voucher. Click here for the survey 👉 bit.ly/3ZAiPP8 #HEOR #healtheconomics #medicaleconomics
bit.ly
Trending Topics in Pharmacoeconomics: 2025 – 2026
000
Journal of Medical Economics @jme-journal.bsky.social · 18/06/2025
📢 Your expert opinion on #pharmacoeconomics trends for 2026 matters! Complete our short survey to share your views, and be in for a chance to win a $40 Amazon gift voucher. Click the link to have your say 👉 bit.ly/3ZAiPP8 #HEOR #healtheconomics #medicaleconomics
survey.alchemer.eu
Trending Topics in Pharmacoeconomics: 2025 – 2026
000
Journal of Medical Economics @jme-journal.bsky.social · 06/06/2025
Looking ahead to 2026: Which #pharmacoeconomic topics will have the most impact? Share your expertise in this important discussion by completing our brief survey 👉 invt.io/1bxbq6unbf0 The results will be shared in an upcoming article in Taylor & Francis's health economics journals. #HEOR
invt.io
Complete our Survey
Click Here
000
Journal of Medical Economics @jme-journal.bsky.social · 04/06/2025
🚨New Article🚨 Read our latest article titled "Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs". Click to view the article in full 👉 bit.ly/452YBB1 #HEOR #Healtheconomics #Pharmacoeconomics #NICE #technologyappraisals
bit.ly
Use of external data to inform overall survival extrapolation in NICE technology appraisals for oncology drugs
To assess use of external evidence for overall survival (OS) estimation in oncology single-technology appraisals (STAs) by the National Institute for Health and Care Excellence (NICE).STAs for onco...
010
Journal of Medical Economics @jme-journal.bsky.social · 29/04/2025
Excited to be attending ISPOR Annual in Montreal, reach out if you are attending too and would like to connect! #ispor2025 #ispor #heor #healtheconomics #outcomesresearch #healthpolicy #medicaleconomics #pharmacoeconomics
010
Journal of Medical Economics @jme-journal.bsky.social · 11/04/2025
#Taylor&Francis commemorates 15 years of 𝗦𝗧𝗔𝗥 (𝗦𝗽𝗲𝗰𝗶𝗮𝗹 𝗧𝗲𝗿𝗺𝘀 𝗳𝗼𝗿 𝗔𝘂𝘁𝗵𝗼𝗿𝘀 𝗮𝗻𝗱 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀), an initiative aiding independent researchers without institutional affiliations. STAR grants access to cutting-edge research, bridging the gap for scholars worldwide. Learn more👉 bit.ly/4jx3Htl #publishing
bit.ly
Taylor & Francis celebrates 15 years of unique scheme supporting researchers in resource-constrained countries
STAR (Special Terms for Authors and Researchers) gives individual unaffiliated researchers in over 100 countries free access to journal articles.
001
Journal of Medical Economics @jme-journal.bsky.social · 09/04/2025
📢 Exciting opportunity for researchers! 📢 Adding a #graphicalabstract to your article captures a greater audience and increases views. See an excellent example below, to read the article in full, click here 👇 bit.ly/42EeQ5O Want tips on how to make them? Get in touch 👇 mike.gregg@tandf.co.uk
bit.ly
Narrative review of value frameworks in urothelial carcinoma and positioning of enfortumab vedotin
Evaluate existing oncology value frameworks in terms of their methodology, structure, characteristics, and functionality using the example of enfortumab vedotin, an approved therapy for urothelial ...
000
Journal of Medical Economics @jme-journal.bsky.social · 04/04/2025
🚨New article alert🚨 Our latest article looks at the associations between procedural volume, costs, and outcomes of septal reduction therapies for #obstructivehypertrophiccardiomyopathy in US hospitals. To read it in full, click the link 👉 bit.ly/42wHFkA #HEOR #healtheconomics #Cardiovascularhealth
bit.ly
Associations between procedural volume, costs, and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy in US hospitals
We assessed the relationship between hospital septal reduction therapy (SRT) procedural volume and clinical outcomes, healthcare resource utilization, and hospital costs.This cross-sectional study ...
000
Journal of Medical Economics @jme-journal.bsky.social · 02/04/2025
🚨Journal news🚨 We are delighted to announce that Ishveen Chopra has joined our #EarlyCareerPanel. Ishveen is a seasoned leader in #HEOR, with a distinctive background spanning clinical, translational, and analytical research. We are excited to work with Ishveen to support her career.
000
Journal of Medical Economics @jme-journal.bsky.social · 31/03/2025
🚨Available now!🚨 Read our latest article that analyzes the cost-effectiveness of various treatments for #haemophilia. Click the link for the full article 👉 bit.ly/3FN2GPb #costeffectiveness #HEOR #healtheconomics #pharmacoeconomics
bit.ly
Systematic review of cost-effectiveness modelling studies for haemophilia
Haemophilia is a rare genetic disease that hinders blood clotting. We aimed to review model-based cost-effectiveness analyses (CEAs) of haemophilia treatments, describe the sources of clinical evid...
000
Journal of Medical Economics @jme-journal.bsky.social · 26/03/2025
Take a deep dive into what articles our readers viewed most last year and discover the Editor in Chief's recommended reads, which he selected based on their innovation and impact. Read the article in full here 👉 bit.ly/4c4oXnD #HEOR #Healtheconomics #pharmacoeconomics #medicaleconomics
bit.ly
2024 in review: high impact articles from the Journal of Medical Economics
Published in Journal of Medical Economics (Vol. 28, No. 1, 2025)
100
Journal of Medical Economics @jme-journal.bsky.social · 25/03/2025
Interested in how #plainlanguagesummaries can benefit your articles? Discover this and a lot more in our "𝐡𝐨𝐰 𝐭𝐨 𝐰𝐫𝐢𝐭𝐞 𝐚 𝐩𝐥𝐚𝐢𝐧 𝐥𝐚𝐧𝐠𝐮𝐚𝐠𝐞 𝐬𝐮𝐦𝐦𝐚𝐫𝐲" guide, available here 👉 bit.ly/3tUaWkX #PLS #laysummary #Taylor&Francis #healtheconomics #HEOR
bit.ly
How to write and publish a Plain Language Summary |
Learn why you should create a Plain Language Summary (PLS), the different types, and how to write and develop your PLS for publication.
010
Journal of Medical Economics @jme-journal.bsky.social · 24/03/2025
🚨Available now🚨 Discover the cost-effectiveness of #semaglutide in people with #obesity and #cardiovasculardisease without #diabetes in this latest article in the Journal of Medical Economics Click the link for the full article 👉 bit.ly/4c7JlEn #costeffectiveness #HEOR #pharmacoeconomics
bit.ly
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight o...
010
Journal of Medical Economics @jme-journal.bsky.social · 21/03/2025
🚨Now online🚨 An incredibly insightful original research article published last week in the Journal of Medical Economics, to access it in full click here 👉 bit.ly/4iB3XHc Big thanks to the authors for publishing in JME.
bit.ly
Assessing the economic impact and healthcare resource utilization of inpatient pneumococcal disease among adults: a French national claims database study
Pneumococcal diseases (PD) caused by Streptococcus pneumoniae include invasive PD (IPD) and non-bacteremia pneumococcal pneumonia (NBPP). Current French vaccination guidelines focus on patients wit...
010
Journal of Medical Economics @jme-journal.bsky.social · 20/03/2025
Using #videoabstracts to discuss and summarise the findings of a paper is increasing in popularity for our authors. Below is a fantastic example, if you want to learn how to make them get in touch 👉 mike.gregg@tandf.co.uk To view the paper in full click here👉 bit.ly/4ihgK1O vimeo.com/1036790510
vimeo.com
Video Abstract - Comparison of acalabrutinib versus ibrutinib in relapsed/refractory mantle cell lymphoma
https://www.tandfonline.com/doi/full/10.1080/13696998.2024.2422227 © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
010
Journal of Medical Economics @jme-journal.bsky.social · 19/03/2025
🚨Essential read🚨 The 𝙅𝙤𝙪𝙧𝙣𝙖𝙡 𝙤𝙛 𝙈𝙚𝙙𝙞𝙘𝙖𝙡 𝙀𝙘𝙤𝙣𝙤𝙢𝙞𝙘𝙨 𝙧𝙚𝙫𝙞𝙚𝙬 𝙤𝙛 𝟮𝟬𝟮𝟰, which consists of the journal's 𝐭𝐨𝐩 𝐟𝐢𝐯𝐞 𝐦𝐨𝐬𝐭 𝐯𝐢𝐞𝐰𝐞𝐝 𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬 and Editor in Chief 𝐬𝐞𝐥𝐞𝐜𝐭𝐞𝐝 𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬, which he picked for their innovation and impact. To read the article in full click the link 👉 bit.ly/4jEZRzd #HEOR #Healtheconomics
010
Journal of Medical Economics @jme-journal.bsky.social · 18/03/2025
🚨 Now online🚨 Discover the budget impact of #resmetirom as a treatment for adults with non-cirrhotic non-alcoholic steatohepatitis with moderate-to-advanced liver fibrosis and estimated total costs for a hypothetical US private payer. Read the article here👉 bit.ly/4iWpfiq #liverdisease #HEOR
bit.ly
Budget impact of resmetirom for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)
This study assessed the budget impact of resmetirom as a treatment for adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate-to-advanced liver fibrosis and estimated total co...
010
Journal of Medical Economics @jme-journal.bsky.social · 17/03/2025
🎉Delighted to share our first plain language summary of publication on #transcatheteraorticvalvereplacement. Click the link to view the article in full 👉 bit.ly/3Fq36L2 Want to find out more about this article type, let me know: mike.gregg@tandf.co.uk #plsp #HEOR #healtheconomics #plainlanguage
010